Phase II clinical trial to evaluate the efficacy and safety of first-line treatment with atezolizumab in combination with paclitaxel and bevacizumab (Avastin®) in patients with advanced or metastatic triple-negative breast cancer. ATTRACTIVE
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: MEDICA SCIENTIA INNOVATION RESEARCH, SL
- Phase: II
- Execution start: 21/05/2021
- End of execution: 30/03/2023
- IP: ISABEL BLANCAS LOPEZ-BARAJAS